Waiv Enters Collaboration with Daiichi Sankyo to Deliver AI-Derived Biomarkers for ADC Program
Waiv, formerly Owkin Dx, a Paris-based company catalyzing AI precision testing, today announced it has entered a collaboration with Daiichi Sankyo (TSE: 4568) to lead digital pathology biomarker discovery for an antibody-drug conjugate (ADC) program.
Waiv Secures $33 Million to Scale AI Precision Testing
Waiv, a Paris-based company catalyzing AI precision testing, today announced a $33 million financing round to accelerate the global deployment of its AI precision testing platform. The financing marks Waiv’s spin out from Owkin, where its experienced team previously operated as Owkin Dx. The raise is co-led by OTB Ventures and Alpha Intelligence Capital (AIC), with participation from Serena Data Ventures, Karista, and SistaFund.
